HomeCompareTTOO vs MRK

TTOO vs MRK: Dividend Comparison 2026

TTOO yields 666666.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TTOO wins by $8.275235618773884e+34M in total portfolio value
10 years
TTOO
TTOO
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full TTOO calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TTOO vs MRK

📍 TTOO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTTOOMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TTOO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TTOO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TTOO
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, TTOO beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TTOO + MRK for your $10,000?

TTOO: 50%MRK: 50%
100% MRK50/50100% TTOO
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TTOO
Analyst Ratings
1
Strong
2
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$5.00
+1666566.7% upside vs current
Range: $5.00 — $5.00
Altman Z
-55.6
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TTOO buys
0
MRK buys
0
No recent congressional trades found for TTOO or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTTOOMRK
Forward yield666666.67%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8.275235618773884e+34M$56.8K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$8.275075881065991e+34M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$5.00$128.54

Year-by-year: TTOO vs MRK ($10,000, DRIP)

YearTTOO PortfolioTTOO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,206$366.19+$66.67MTTOO
2$415,506,651,117$415,435,306,334.37$12,650$502.35+$415506.64MTTOO
3$2,419,908,598,386,268$2,419,464,006,269,573.00$14,407$694.19+$2419908598.37MTTOO
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$16,585$967.82+$13171697643084.44MTTOO
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$19,342$1,363.89+$67004927492790120.00MTTOO
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$22,913$1,947.19+$318562277003514871808.00MTTOO
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$27,662$2,823.89+$1.415484168853553e+24MTTOO
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$34,159$4,173.35+$5.878130573362507e+27MTTOO
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$43,337$6,308.80+$2.2813793009840744e+31MTTOO
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$8.275235618773884e+34MTTOO

TTOO vs MRK: Complete Analysis 2026

TTOOStock

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Full TTOO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TTOO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TTOO vs SCHDTTOO vs JEPITTOO vs OTTOO vs KOTTOO vs MAINTTOO vs JNJTTOO vs ABBVTTOO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.